Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01975116 · ClinicalTrials.gov registry record · Phase 1
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01975116 is a Phase 1 study that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 18 participants.
The verdict
NCT01975116, a Phase 1 study, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors. Drugs used in chemotherapy, such as azurin-derived cell-penetrating peptide p28, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- DRUG azurin-derived cell-penetrating peptide p28
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01975116
The ClinicalTrials.gov registry entry for NCT01975116 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which azurin-derived cell-penetrating peptide p28 is the first listed.
NCT01975116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01975116 about?
NCT01975116 is a clinical study titled "p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors". This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors. Drugs used in chemotherapy, such as azurin-derived cell-penetrating peptide p28, work in different ways to ...
What is the current status of trial NCT01975116?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-08. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01975116?
The interventions under investigation include: azurin-derived cell-penetrating peptide p28 (DRUG).
Who is sponsoring clinical trial NCT01975116?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.